Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BriaCell Therapeutics Corp.
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
May 10, 2026
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
May 8, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
May 8, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
May 7, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
May 5, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
May 3, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
May 2, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
May 1, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
April 28, 2026
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
April 28, 2026
←
Previous Page
1
2
3
Next Page
→